NADAC acquisition cost data for HUMIRA(CF) 40 MG/0.4 ML SYRINGE. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00074024302 | $3,123.51 | 2022-01-14 | Rx |
| 00074024302 | $3,123.51 | 2022-01-14 | Rx |
| 00074024302 | $3,123.51 | 2022-01-14 | Rx |
| 00074024302 | $3,123.51 | 2022-01-14 | Rx |
| 00074024302 | $3,123.51 | 2022-01-14 | Rx |
| 00074024302 | $3,123.51 | 2022-01-14 | Rx |
| 00074024302 | $3,123.51 | 2022-01-14 | Rx |
| 00074024302 | $3,123.51 | 2022-01-14 | Rx |
| 00074024302 | $3,123.51 | 2022-01-14 | Rx |
| 00074024302 | $3,123.51 | 2022-01-14 | Rx |
Generic: Adalimumab | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $175.8M | 26,325 | 5,302 | $2,633.89 |
| 2020 | $305.6M | 41,732 | 6,775 | $2,831.05 |
| 2021 | $366.7M | 47,902 | 7,127 | $3,066.38 |
| 2022 | $410.2M | 49,564 | 7,125 | $3,307.27 |
| 2023 | $445.8M | 49,828 | 7,030 | $3,609.32 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Texas | $36.6M | 4,073 | 587 |
| New York | $33.6M | 3,620 | 541 |
| California | $31.7M | 3,634 | 568 |
| Florida | $29.0M | 3,273 | 484 |
| Pennsylvania | $23.0M | 2,402 | 319 |
| Michigan | $19.2M | 2,187 | 301 |
| Massachusetts | $16.5M | 1,778 | 232 |
| North Carolina | $16.2M | 1,748 | 229 |
| Ohio | $15.7M | 1,665 | 254 |
| Puerto Rico | $13.4M | 1,866 | 220 |
| Illinois | $13.0M | 1,404 | 199 |
| Georgia | $12.9M | 1,423 | 211 |
| Missouri | $11.9M | 1,245 | 182 |
| Tennessee | $10.6M | 1,153 | 170 |
| Arizona | $10.5M | 1,251 | 187 |
| Washington | $10.2M | 1,097 | 182 |
| Wisconsin | $8.7M | 982 | 147 |
| New Jersey | $8.6M | 1,033 | 156 |
| Indiana | $8.5M | 991 | 129 |
| Colorado | $7.7M | 895 | 131 |
| South Carolina | $7.4M | 720 | 125 |
| Kentucky | $7.4M | 893 | 127 |
| Louisiana | $7.0M | 769 | 107 |
| Virginia | $6.8M | 734 | 118 |
| Alabama | $6.0M | 683 | 95 |
| Oklahoma | $5.9M | 654 | 120 |
| Minnesota | $5.8M | 610 | 94 |
| Connecticut | $5.6M | 543 | 87 |
| Oregon | $5.5M | 705 | 95 |
| Iowa | $4.9M | 558 | 72 |
| Maryland | $4.7M | 500 | 84 |
| Arkansas | $4.2M | 486 | 77 |
| Mississippi | $4.2M | 477 | 68 |
| New Mexico | $3.4M | 396 | 55 |
| West Virginia | $3.4M | 409 | 62 |
| Utah | $3.2M | 402 | 56 |
| Maine | $2.9M | 327 | 49 |
| Montana | $2.3M | 267 | 33 |
| Idaho | $2.2M | 242 | 40 |
| Nevada | $2.1M | 258 | 46 |
| Nebraska | $1.8M | 236 | 31 |
| Alaska | $1.7M | 159 | 25 |
| Kansas | $1.5M | 167 | 28 |
| New Hampshire | $1.5M | 169 | 30 |
| Vermont | $1.3M | 136 | 17 |
| North Dakota | $1.0M | 116 | 13 |
| Delaware | $1.0M | 119 | 17 |
| South Dakota | $1.0M | 114 | 20 |
| Hawaii | $654.3K | 81 | 11 |
| District of Columbia | $599.6K | 65 | 12 |
| Rhode Island | $581.9K | 68 | 13 |
| Wyoming | $249.7K | 35 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.